- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- La Mesa, California • Oklahoma City, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab (SAR440340), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Tucson, Arizona • La Palma, California + 51 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab SAR440340, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 71
- States / cities
- Phoenix, Arizona • Fresno, California • Palm Springs, California + 60 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab SAR440340, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 65 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab SAR440340
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Torrance, California • Denver, Colorado • Miami, Florida + 4 more
- Conditions
- Asthma
- Interventions
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab AI, Itepekimab PFS
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Bronchiectasis
- Interventions
- Itepekimab (SAR440340), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more